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Abstract
Summary The effects of COVID-19 have the potential to impact on the management of chronic diseases including osteoporosis.
A global survey has demonstrated that these impacts include an increase in telemedicine consultations, delays in DXA scanning,
interruptions in the supply of medications and reductions in parenteral medication delivery.
Introduction The COVID-19 pandemic has had profound effects on the health of the global population both directly, via the
sequelae of the infection, and indirectly, including the relative neglect of chronic disease management. Together the International
Osteoporosis Foundation and National Osteoporosis Foundation sought to ascertain the impact on osteoporosis management.
Methods Questionnaires were electronically circulated to a sample of members of both learned bodies and included information
regarding the location and specialty of respondents, current extent of face to face consultations, alterations in osteoporosis risk
assessment, telemedicine experience, alterations to medication ascertainment and delivery and electronic health record (EHR)
utilisation. Responses were collected, quantitative data analysed, and qualitative data assessed for recurring themes.
Results Responses were received from 209 healthcare workers from 53 countries, including 28% from Europe, 24% from North
America, 19% from the Asia Pacific region, 17% from the Middle East and 12% from Latin America. Most respondents were
physicians (85%) with physician assistants, physical therapists and nurses/nurse practitioners represented in the sample. Themain
three specialties represented included rheumatology (40%), endocrinology (22%) and orthopaedics (15%). In terms of the type of
patient contact, 33% of respondents conducted telephone consultations and 21% video consultations. Bone mineral density
assessment by dual-energy X-ray absorptiometry (DXA) usage was affected with only 29% able to obtain a scan as recommend-
ed. The majority of clinicians (60%) had systems in place to identify patients receiving parenteral medication, and 43% of
clinicians reported difficulty in arranging appropriate osteoporosis medications during the COVID-19 crisis.
Conclusions To conclude through surveying a global sample of osteoporosis healthcare professionals, we have observed an
increase in telemedicine consultations, delays in DXA scanning, interrupted supply of medications and reductions in parenteral
medication delivery.
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Introduction
The COVID-19 pandemic has assaulted healthcare sys-
tems and brought crippling societal and financial changes
which are becoming more apparent every day. The health
impacts of COVID-19 are both direct, as a consequence
of the infection itself, and indirect, due to interruption in
routine and preventive health care services and in the
management of chronic diseases. Lock-downs, self-
isolation and shielding have necessitated a move away
from face to face encounters toward alternative models
of care, including telemedicine [1–3]. There have also
been logistic challenges with ascertainment and delivery
of goods (including medications [4]) and the necessary
redeployment of staff to in-patient units has likely impact-
ed out-patient services. The assessment and management
of osteoporosis is largely performed in these out-patient
settings and, combined with the prescribing and delivery
of anti-osteoporosis medications, is likely to have been
hampered by the COVID-19 pandemic. Indeed, access to
the online FRAX® fracture risk assessment tool was al-
most 60% lower in April compared to February 2020 sug-
gesting that osteoporosis assessment may have been
neglected during the pandemic [5].
The International Osteoporosis Foundation (IOF) and
National Osteoporosis Foundation (NOF) aimed to character-
ise the specific impact of COVID-19 on the care, assessment
andmanagement of osteoporosis patients through a survey put
to a sample of the IOF and NOF membership.
Methods
Surveys for the management and treatment of osteoporosis
during the COVID-19 crisis were composed by CG, AM,
AP and AS from the NOF and shared with members of the
IOF including CC, NCH and JYR for use by IOF and their
associated membership. The surveys covered the location and
specialty of respondents, current extent of face to face consul-
tations, alterations in osteoporosis risk assessment, telemedi-
cine experience, alterations to medication ascertainment and
delivery and electronic health record (EHR) utilisation.
The NOF survey was conducted between April 15 and 24,
2020, using the SurveyMonkey platform. The survey was sent
to 400 healthcare providers in NOF’s Professional Partner
Network membership programme with one reminder circulat-
ed during this period. The IOF survey was conducted between
May 18 and June 8, 2020, using the SurveyMonkey platform.
The survey was sent to 526 healthcare providers from the IOF
Committee of Scientific Advisors and the Committee of
National Societies with four reminders circulated during this
period.
Data were collected, merged where appropriate and
depicted graphically using bar charts, and free text responses
were assessed for recurring themes.
Results
There were 209 respondents from a total of 53 countries,
including 28% from Europe, 24% from North America,
19% from the Asia Pacific region, 17% from the Middle
East and 12% from Latin America. The majority of re-
spondents were physicians (85%) with 7% physician as-
sistants, 2% physical therapists, 3% nurses/nurse practi-
tioners and 3% other (in management). Respondents rep-
resented the specialties of rheumatology (40%), endocri-
nology (22%), orthopaedics (15%), general internal med-
icine (11%), radiology (3%), obstetrics and gynaecology
(2%), physical medicine (1%), nephrology (0.5%) and
other (4% including osteology, bone metabolism, geriatric
medicine and management), and were primarily affiliated
with academic medical centres or hospital-based clinics
(Fig. 1).
Regarding office, clinic or hospital closures, 21% of insti-
tutions were open to patients for face to face or telemedicine
consultations for emergencies only, 23% for non-acute or rou-
tine visits, 57% for both emergency and routine appointments
and 7% were closed to all visit types.
In terms of the mode of patient contact, 33% of respondents
performed telephone consultations, 21% video consultations,
26% face to face appointments, 18% urgent ‘in person’ visits,
and 3% used other modalities, including instant messaging or
attendance for parenteral therapies.
Regarding which patients were considered suitable for ‘vir-
tual’ appointments, 28% of the providers conducted telemed-
icine appointments for established patients requiring diagnos-
tic services, 40% conducted telemedicine appointments for
established patients requiring treatment decisions, 19%























Fig. 1 Clinical settings represented by respondents to surveys (% of total
responses)
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patients’ (including those affected by COVID-19 or those un-
dergoing quarantine who required repeat prescription of med-
ication) and 10% did not conduct any telemedicine
appointments.
When considering how to incorporate DXA into osteopo-
rosis risk assessment, 29% scheduled a DXA as soon as pos-
sible in order to inform treatment decisions (with appropriate
precautions being taken), 11% assessed patients based on a
clinical risk calculator (e.g. FRAX®) alone, 29% assessed
patients based on a clinical risk calculator with a planned
DXA at a later date and 33% arranged a DXA for when the
risk of COVID-19 infection was likely to have lessened. A
total of 5% responded that their DXA unit was currently
closed or that they were referring to an osteoporotic fracture
clinic service.
Reimbursement for telemedicine appointments was possi-
ble for 48% of respondents, but unavailable for 20% of re-
spondents. A total of 14% of providers were unsure about
reimbursement policies or status, and 17% stated that this
was not applicable to their health care system or funding
stream (Fig. 2). The number of weekly telemedicine appoint-
ments ranged from none to more than 20 (Fig. 3).
Almost half of clinicians, 43%, reported difficulty in ar-
ranging for appropriate osteoporosis medications during the
COVID-19 crisis, whilst 57% reported no issues. Of those
reporting problems, the overarching reasons included limited
supply of or difficulty in acquiring medications, delay in ad-
ministration of parenteral agents normally provided by a
healthcare professional (both infusions and injections), reluc-
tance on the part of patients to present for medication admin-
istration appointments even when opportunities existed and
travel restrictions and self-isolation, resulting in patients being
unable to attend office visits for administration of medica-
tions. Further details and specific comments from respondents
are shown in Table 1.
During the COVID-19 pandemic, healthcare workers dif-
fered in their approach to medication prescriptions: 28%
prescribed refills only, 3% made new prescriptions only,
63% prescribed both refills and new prescriptions and 4%
did not prescribe any medication unless it was for an acute
indication or illness.
For those patients requiring a ‘healthcare professional-








Yes No Not sure Not applicable
Fig. 2 Ability to request reimbursement for telemedicine appointments







None 1-5 6-10 11-15 16-20 More than 20
Fig. 3 Number of telemedicine consultations per week (% of total
respondents)
Table 1 A sample of responses to the question ‘Please explain the
issues you’re having with getting your patients their appropriate
osteoporosis medication’
I have decided to start second-line treatment with zoledronate, teriparatide
or denosumab
Irregular deliveries of medicine—denosumab in particular
Routine infusions, e.g.: zoledronate paused and difficulties for
denosumab for shielded patients
Limited access to IV zoledronate
Intravenous infusion of zoledronate due to a need to visit the infusion unit
Intravenous medications might be difficult to receive, but the delay of
3–4 months is not a very big issue for zoledronic acid.
Zoledronate infusions were suspended for 2 months but denosumab
continues
Bisphosphonates are sometimes lacking to logistic problems and
embargo.
Some primary care physicians are closed therefore some patients are
having their denosumab delayed. I see these patients and give them the
medication
Medicines not available
Some who need injectable medications avoid visiting clinic
Patients in quarantine—prescriptions by email
Patients were afraid to consult and preferred to postpone the consultation
and medication
Teriparatide injections (issue with cost of the drug and obtaining it)
Difficulty in administering denosumab injections, zoledronate infusions.
Many patients have skipped their injectable medications and follow up
appointments
They do not like or are afraid to come to the out-patient clinic as before,
because of the COVID-19 pandemic. Some of them just no show.
My overseas patients are unable to visit and those locally are unable to get
their denosumab there as it is not registered in my country
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zoledronate or romosozumab), 46% felt they had sufficient
safeguards in place to minimise patient risk for in person med-
ication administration visits, 3% had moved these treatments
to an alternate clinical location, 21% suggested delaying treat-
ment until COVID-19 risk had abated, 13% recommended a
switch to an oral medication and 8% considered arranging in-
home administration of treatment. In the 9% of ‘other’ re-
sponses, clinicians stated that the decision was made on a
patient-by-patient basis, denosumab was self-administered
by the patient at home, and they felt that zoledronate admin-
istration could be delayed but denosumab should be continued
on schedule (Fig. 4).
The majority of clinicians (60%) had systems in place to
identify patients receiving subcutaneous or intravenous med-
ication, so that plans of care could be proactively discussed
with them. According to responders, primary care physicians
were responsible for prescription of oral bisphosphonates in
49% of responses, raloxifene in 12%, denosumab in 15%,
zoledronate in 8%, menopausal hormone therapy (MHT) in
7% and other medications in 9% of responses (see Fig. 5).
Regarding the amount of time required for electronic health
record (EHR) charting or input during the COVID-19 pan-
demic, the majority of providers (93%) reported that it took
as much or more time than that allotted prior to the pandemic
(supplementary Fig. 1). Of those reporting changes in time for
EHR documentation and overall care, the reasons included
communication and documentation issues (e.g. more time tak-
en to document, provide adequate reassurance and explana-
tions to patients, difficulty contacting patients), technical
issues (e.g. poor internet connection, software problems,
balancing multiple channels of communication, assisting the
patient in the use of the video conferencing platform), work-
flow-related issues (e.g. difficulty acquiring prior patient
notes/records due to closure of the hospital records section,
greater complexity of work-flow, increased screening required
for each patient to assess suitability for telemedicine appoint-
ment), treatment issues (e.g. inefficiencies in pharmacy oper-
ation during the pandemic, paucity of available treatments)
and safety issues (e.g. additional time required for COVID-
19 screening of patients prior to appointments, increased spac-
ing of patient visits due to sanitising between appointments
and social distancing between patients).
The time taken to follow-up patients was reported as great-
er in 39% of respondents, less in 9%, no change in 45% and
7% of respondents were unsure. Of those reporting greater
time taken the reasons included communication with the pa-
tient (e.g. older persons being reticent to meet via telemedi-
cine, more time required to provide explanations, responding
to COVID-19 related concerns, clinicians providing laborato-
ry results over the phone, clinicians calling to rearrange ap-
pointments), patient care (e.g. patients using specialist ap-
pointments to address all medical issues due to a paucity of
medical availability elsewhere, extra time required for
sanitisation, assessment of patient risk for COVID-19, com-
plexity of EHR). In those reporting less time taken, the reasons
included a greater time-efficiency of telephone consultations
and spending more time with patients on video calls as fewer











































Fig. 4 Action for patients due to
receive an HCP-administered os-
teoporosis treatment, who have
conditions that would increase the
risks associated with COVID-19
exposure (% of total responses)
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In the USA, 53% of the physicians were aware that
Medicare allowed greater flexibility for therapies normally
administered in a clinical setting and covered under
Medicare part B to be administered at home; it should be noted
that this often changed coverage to Medicare part D and in-
creased out of pocket expenses for patients. Whilst 61% con-
sidered utilising this new Medicare arrangement, 27% were
not sure and 12% would not consider using this option. The
main reasons for not considering home administration were
either that they were unaware, that this was not a substantial
issue for them or they would rather use medications covered
under Medicare part D (self-injection or oral medications), in
order to ensure access to treatment and avoid the potential
spread of COVID-19.
Discussion
COVID-19 has had profound effects on global societies, fi-
nances and healthcare. We have captured some of the pro-
found alterations in osteoporosis assessment and treatment
from a broad cross-section of healthcare providers who have
managed patients at risk of fragility fractures during the
pandemic.
The way in which osteoporosis care is offered has pro-
foundly changed with almost 1 in 3 healthcare providers
performing telephone consultations and 1 in 5 performing
video consultations. Over a fifth of respondents reported over
20 telemedicine appointments per week. It will be interesting
to see whether this modality of patient contact continues to be
widely accepted and used as lock-downs lift and we return to
the ‘new normal’. The move toward telemedicine may be
advantageous in the long term with previous studies demon-
strating financial savings and increased efficiencies for
healthcare systems [6], and increased convenience and
satisfaction for patients [7]. However, not all of the potential
benefits may be observed in the short-term.
When patients were seen, a third of healthcare workers
reported that a DXA was arranged without delay, but approx-
imately 2/3 reported delays in obtaining a DXA and 11%
reported use of clinical risk assessment tools (such as
FRAX®) alone without bone mineral density measurement.
The limited or delayed access to DXA may change ‘usual
practice’, as a previous IOF survey of DXA usage identified
that 83% of Fracture Liaison Services (FLS) performed inter-
val scanning to monitor patients, and 50% of new patients
were assessed with DXA [8]. Data from our survey are
concerning and suggest that the traditional gold standard as-
sessment of osteoporosis patients was not performed in the
majority of cases during the pandemic. Anticipating the dis-
ruption of the care of patients with fragility fractures, IOF and
NOF encouraged FLS centres to adopt a simplified model of
care including avoiding delays to assessment and treatment
whilst waiting for a DXA scan.
The long-term impact the COVID-19 pandemic will have
on chronic disease management and global health systems is
difficult to predict. In the short-term, we see immediate chal-
lenges to maintaining appropriate levels of care, particularly
for patients at greater risk for the COVID-19 virus.
In many countries, there appears to be a substantial impact
on reimbursement due to the change in number and type of
patient visits, which may have implications for the ability to
sustain and offer various osteoporosis clinical services and
tests such as DXA. This must be carefully monitored as such
changes could lead to a reduction in resources, a decrease in
the assessment and treatment of patients with osteoporosis and
osteoporosis-related fracture, and could ultimately translate
into increased fracture rates and burden in the future. In some
countries, temporary adjustments made to telemedicine
(phone and video) reimbursement rates during the public
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implications and opportunities. Reimbursement rates will vary
by country, insurance carriers and/or provider.
Changes in EHR were considered to be less time-efficient
than pre-pandemic systems for a third of respondents with a
minority (4%) reporting time-saving with the introduction of
new technologies and telemedicine platforms. Early EHR
studies demonstrated similar findings, as seen in a 2005 sys-
tematic review of time-efficiency in the use of EHR [9]; how-
ever, in the intervening 15 years systems and platforms have
improved with marked benefits and time-efficiency of EHR
demonstrated in the management of COVID-19 in hospitals in
New York [10].
As has been seen with medications for other diseases, the
availability of osteoporosis medications has been affected due
to delivery/logistic issues, patients being unable or reluctant to
attend visits for subcutaneous injections or intravenous infu-
sions, and some additional problems, including primary care
closures removing ready access to denosumab injections in
the community. A fifth of respondents reported delays in pro-
viding intravenous or subcutaneous medication, and 13% re-
ported a policy of switching patients to oral formulations to
allow therapy to continue in the absence of parenteral treat-
ments. A third of respondents only prescribed refill (or repeat)
medication and no new medications with potentially serious
consequences for new patients or those who had sustained a
new fracture. The NOF, IOF and the Capture the Fracture
websites and recent webinars also provided guidance on oste-
oporosis treatment in the event of medication access issues
and delays in administration.
Despite an understandable reticence of patients to attend in-
person appointments, approximately half of healthcare pro-
viders believed that there were sufficient safeguards in place
to mitigate risk and allow in-person visits.
These findings are, of course, limited to those who were
sampled and responded, and therefore, most reflect the input
of rheumatology and endocrine physicians working in an ac-
ademic centre or hospital clinic. Many aspects of our findings
are still relevant to a broader audience of health professionals.
Despite the global reach of COVID-19, it should also be
recognised that some countries were at different points in the
course of the pandemic, which may also be reflected in the
variability of responses received.
In conclusion, through surveying a global sample of oste-
oporosis healthcare professionals, we have observed an in-
crease in telemedicine consultations, greater reliance on
EHR (with perceived time-inefficiencies) and potential im-
pacts on reimbursement, delays to DXA scanning and supply
of medications, reductions in parenteral medication delivery
and an understandable reticence of patients to attend clinic
appointments face to face. These findings serve to highlight
the detrimental effects the COVID-19 pandemic is having on
osteoporosis assessment and management. At worst, this will
result in a rise in fracture rates and a huge increase in individ-
ual morbidity and societal burden.
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